title: Peripheral blood CD14high CD16+ monocytes are main producers of IL-10.
abstract: Based on CD14 and CD16 expression, human peripheral blood monocytes (MO) can be divided into a major CD14(high) CD16(-) population and two minor CD14(high) CD16(+) and CD14(dim) CD16(+) subpopulations. CD14(dim) CD16(+) MO are well characterized and regarded as pro-inflammatory because upon stimulation produce TNF-alpha but little, if any, IL-10. By contrast, little is known about CD14(high) CD16(+) MO. We investigated the surface expression of selected determinants by CD16(+) MO subpopulations, cytokine production, phagocytosis and antigen presentation. We found that both CD16(+) subpopulations had a higher expression of HLA-DR, CD86, CD54 and a lower expression of CD64 than CD14(high) CD16(-) population. In addition, CD14(high) CD16(+) MO showed a higher expression of CD11b and TLR4 than CD14(dim) CD16(+) and CD14(high) CD16(-) subpopulations. CD14(high) CD16(+) MO exhibited an increased phagocytic activity and a decreased antigen presentation in comparison with CD14(dim) CD16(+). As expected, lipopolysaccharide (LPS)-stimulated CD14(dim) CD16(+) MO produced TNF-alpha but little IL-10. By contrast, LPS-stimulated CD14(high) CD16(+) subpopulation produced significantly more IL-10 than CD14(dim) CD16(+) and CD14(high) CD16(-) MO. In conclusion, our data show that human peripheral blood CD16(+) MO are heterogeneous in function and consist of two subpopulations: CD14(dim) CD16(+) pro-inflammatory and CD14(high) CD16(+) with anti-inflammatory potential.
authors.affiliation: Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Cracow, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Skrzeczyńska-Moncznik
authors.forename: M
authors.initials: M
authors.lastname: Bzowska
authors.forename: S
authors.initials: S
authors.lastname: Loseke
authors.forename: E
authors.initials: E
authors.lastname: Grage-Griebenow
authors.forename: M
authors.initials: M
authors.lastname: Zembala
authors.forename: J
authors.initials: J
authors.lastname: Pryjma
mesh_terms: D015703:Antigens, CD / Q000097:blood* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D058851:GPI-Linked Proteins; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis / Q000097:blood* / Q000235:genetics / Q000276:immunology; D018950:Lipopolysaccharide Receptors / Q000097:blood* / Q000276:immunology; D009000:Monocytes / Q000276:immunology*; D010587:Phagocytosis / Q000276:immunology; D010641:Phenotype; D012313:RNA / Q000737:chemistry / Q000235:genetics; D017452:Receptors, IgG / Q000097:blood* / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051193:Toll-Like Receptors / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology
chemical_list: D015703:Antigens, CD; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D018950:Lipopolysaccharide Receptors; D017452:Receptors, IgG; D051193:Toll-Like Receptors; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D012313:RNA